Status:
COMPLETED
Influence of Enteral Microbiome on Mortality of Patients With Cardiogenic Shock
Lead Sponsor:
University Hospital, Essen
Conditions:
Cardiogenic Shock
Microbial Colonization
Eligibility:
All Genders
18+ years
Brief Summary
Cardiogenic shock is associated with a high mortality. The microbiome is a double-edged sword which can convey protective and detrimental cardiovascular effects. The significance of the enteral micobi...
Eligibility Criteria
Inclusion
- \>18y
- signs of cardiogenic shock regardless of etiology
- lactate \>3mmol/L
- and signs of organ dysfunction (urine output \<30 ml/h, cold extremities, altered mental status)
- and systolic blood pressure \<90 mmHg for \>30 minutes or need for vasopressor therapy
Exclusion
- pregnancy/lactation period
- antibiotic treatment within \>24h
- chronic inflammatory bowel disease
- short bowel syndrome
- artificial bowel outlet
- persistent diarrhea or vomiting in the past 3 months
- simultaneous participation in another interfering nutrition study
- active chemo or radiation therapy
Key Trial Info
Start Date :
August 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06006754
Start Date
August 30 2023
End Date
February 15 2025
Last Update
August 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Essen
Essen, North Rhine-Westphalia, Germany, 45147